^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vadacabtagene leraleucel (JCAR015)

    i
    Other names: JCAR015, anti-CD19-CD28-zeta modified CAR CD3+ T lymphocyte therapy, 19-28z T cells, Autologous T cells genetically targeted to the B cell specific antigen CD19
    Associations

    News

    Trials
    Company:
    BMS, Memorial Sloan-Kettering Cancer Center
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    7ms
    T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    7ms
    High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
    10ms
    Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
    P1, N=93, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date
    |
    vadacabtagene leraleucel (JCAR015)
    over1year
    Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    over1year
    High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial completion date • Trial primary completion date
    |
    cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
    almost2years
    Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
    P1, N=93, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    vadacabtagene leraleucel (JCAR015)
    almost2years
    T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2023 --> May 2024 | Trial primary completion date: May 2023 --> May 2024
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement • IKZF1 deletion
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    2years
    Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    over2years
    High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Apr 2022 --> Apr 2023
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
    almost3years
    Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
    P1, N=93, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    vadacabtagene leraleucel (JCAR015)
    almost3years
    T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2022 --> May 2023 | Trial primary completion date: May 2022 --> May 2023
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement • IKZF1 deletion
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    3years
    Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    over3years
    T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2021 --> May 2022 | Trial primary completion date: May 2021 --> May 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement • IKZF1 deletion
    |
    vadacabtagene leraleucel (JCAR015)
    over3years
    High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2021 --> Apr 2022 | Trial primary completion date: Apr 2021 --> Apr 2022
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)
    almost4years
    Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 (clinicaltrials.gov)
    P1, N=93, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2021 --> Jan 2022
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    vadacabtagene leraleucel (JCAR015)
    over4years
    T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2020 --> May 2021 | Trial primary completion date: May 2020 --> May 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement • IKZF1 deletion
    |
    vadacabtagene leraleucel (JCAR015)